Lexeo Therapeutics (LXEO) vs Surrozen (SRZN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Surrozen (SRZN) has outperformed Lexeo Therapeutics (LXEO) over the past year, gaining 99.2% versus a loss of 60.3%. Surrozen is the larger company by market cap ($328.7 million vs $263.5 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LXEO | SRZN |
|---|---|---|
| Share price | $3.21 | $27.97 |
| Market cap | $263.50M | $328.75M |
| 1-day change | -3.02% | +11.23% |
| YTD return | -66.67% | +23.76% |
| 1-year return | -60.31% | +99.22% |
| 5-year return | — | -73.48% |
| EPS (TTM) | $-1.02 | $-39.08 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $10.99 | $37.83 |
| 52-week low | $2.98 | $11.39 |
| Distance from 52-week high | -70.79% | -26.06% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +532.40% | +73.04% |
| Average volume | 1.17M | 475.02K |
| Shares outstanding | 82.09M | 11.75M |
| Employees | 63 | 44 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SRZN has outperformed LXEO by 159.5 percentage points over the past year.
About Lexeo Therapeutics
LXEO stock →Lexeo Therapeutics, Inc., a clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States. Its product pipeline comprises LX2006, an AAVrh10-based gene therapy candidate, which is in phase 1/2 clinical trial to treat friedreich ataxia cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate, which is in phase 1/2 to deliver a functional plakophilin-2 (PKP2) gene to cardiac muscle for the treatment of PKP2-ACM; and LX2021, a gene therapy candidate, which is in preclinical trial to deliver the coding sequence for the functional connexin 43, or Cx43, protein for a group of inherited cardiac muscle disorders associated with a high risk of sudden death, including arrhythmogenic cardiomyopathy (ACM) and certain forms of dilated cardiomyopathy.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 63 employees
About Surrozen
SRZN stock →Surrozen, Inc., a biotechnology company, discovers and develops product candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the eye, intestine, liver, lung, retina, kidney, cochlea, cornea, skin, pancreas, and central nervous system.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 44 employees
LXEO vs SRZN FAQ
Which is bigger, Lexeo Therapeutics or Surrozen?
Surrozen (SRZN) is larger, with a market capitalization of $328.75M compared with $263.50M for Lexeo Therapeutics (LXEO).
Which stock has performed better over the past year, LXEO or SRZN?
SRZN returned +99.22% over the past 12 months, compared with -60.31% for LXEO (price return, excluding dividends). Past performance does not predict future results.
Are Lexeo Therapeutics and Surrozen in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.